Nanomedicine formulations for respiratory infections by inhalation delivery: Covid-19 and beyond
Author:
Open Access
- 3 January 2022
- journal article
- research article
- Published by Elsevier in Medical Hypotheses
- Vol. 159, 110753
Abstract
No abstract availableKeywords
All Related Versions
This publication has 28 references indexed in Scilit:
- Inhibition of A/Human/Hubei/3/2005 (H3N2) influenza virus infection by silver nanoparticles in vitro and in vivoInternational Journal of Nanomedicine, 2013
- Pathogenesis of Viral Respiratory Infection2013
- Aerosolized Antibiotics for Ventilator-associated PneumoniaAnesthesiology, 2012
- Recovery from silver-nanoparticle-exposure-induced lung inflammation and lung function changes in Sprague Dawley ratsNanotoxicology, 2012
- Silver Nanoparticles as Potential Antiviral AgentsMolecules, 2011
- Nanosilver induces minimal lung toxicity or inflammation in a subacute murine inhalation modelParticle and Fibre Toxicology, 2011
- Mode of antiviral action of silver nanoparticles against HIV-1Journal of Nanobiotechnology, 2010
- Synthesis and antibacterial activity of silver nanoparticles with different sizesJournal of Nanoparticle Research, 2008
- A Preliminary Assessment of Silver Nanoparticle Inhibition of Monkeypox Virus Plaque FormationDiscover Nano, 2008
- Characterization of silver nanoparticles synthesized on titanium dioxide fine particlesNanotechnology, 2008